Medical device supply chains face persistent pressure as federal glove push falls short

Nearly $1 billion in federal support has not produced a self-sustaining U.S. medical glove industry, Modern Healthcare reported on July 10, 2026. Hospitals and their supply chain teams remain dependent on imported nitrile gloves, with no domestic manufacturer yet operating at commercial scale. The result is a procurement exposure that federal spending alone has not been able to close.

Import dependency persists despite federal investment

The failure to build domestic glove capacity is one of the clearest illustrations of how difficult near-shoring critical consumables has proven in practice. Nitrile gloves are a high-volume, low-margin product, and established Asian manufacturers have been difficult to displace on cost. For hospital supply chain directors, this means import risk management, not domestic sourcing, remains the dominant strategy for this category.

That risk compounds when paired with active product shortages elsewhere in the supply base. Modern Healthcare reported in June 2026 that providers are navigating shortfalls in critical surgical and diagnostic supplies tied to Medline and Hologic, with disruptions expected to continue through year-end. Hospitals are being forced to identify substitute products, renegotiate distribution contracts, and in some cases delay elective procedures tied to affected product categories.

Ambulatory shift creates new openings for robotic surgery

While consumable supply chains are under stress, the capital equipment side of medtech is seeing a different kind of pressure: opportunity. Distalmotion CEO Greg Roche told Modern Healthcare in June that the ongoing push to migrate procedures from hospital ORs to ambulatory surgery centers is directly benefiting the company. Robotic systems designed for outpatient environments, rather than large hospital suites, are gaining traction as health systems look to reduce per-procedure costs and free up inpatient capacity.

This mirrors a broader structural shift that procurement and VP-level operations leaders need to factor into capital planning. Systems evaluated for an acute-care OR five years ago may not be the right fit for the ASC environment now being prioritized. Footprint, per-procedure economics, and service contract structures all differ.

Imaging infrastructure gets a rethink

Helium-free MRI technology is gaining traction among hospital facility planners, Modern Healthcare reported in June 2026, with providers including Mayo Clinic exploring the technology as a way to expand imaging capacity without the logistical and cost burden of liquid helium supply chains. For health system operations teams, the appeal is partly about procurement simplification and partly about siting flexibility: helium-free systems can be installed in locations where running cryogen supply lines would have been prohibitive.

On the partnership side, WellSpan Health and Philips announced a seven-year agreement in June 2026 to co-develop imaging technology and AI diagnostic tools. The alliance is a signal that long-duration strategic vendor relationships, rather than one-off capital purchases, are becoming a preferred model for health systems looking to keep pace with imaging and AI innovation without bearing full development risk.

Heart valve market heats up with Boston Scientific's $1.5B move

Boston Scientific's $1.5 billion commitment to the transcatheter aortic valve replacement market, reported by Modern Healthcare in May 2026, puts direct pressure on Edwards Lifesciences, the current market leader in TAVR devices. For cardiac program directors and interventional cardiology procurement teams, a more competitive TAVR market typically means more options at the evaluation table and, over time, downward pressure on device pricing.

Meanwhile, Danaher finalized its acquisition of Masimo in June 2026, making the patient monitoring company a wholly owned subsidiary. Masimo CEO Katie Szyman stepped down following the close. For existing Masimo customers, the integration into Danaher's life sciences portfolio raises near-term questions about product roadmaps, service contract ownership, and account management continuity that procurement teams should be clarifying now with their Danaher representatives.

What this means for your team

• Audit glove and surgical consumable sourcing for single-country concentration; the federal investment data confirms domestic backup supply is not a near-term option.
• Contact Medline and Hologic account teams now to get written timelines on shortage resolution and begin evaluating qualified substitutes for affected SKUs before year-end disruptions deepen.
• Revisit capital equipment criteria for surgical robotics and MRI if your system is accelerating ASC expansion or new facility development; product specs optimized for acute care may not translate.
• If your organization holds Masimo contracts, formally request a service and roadmap briefing from Danaher to understand how the acquisition affects terms, support, and future device integration.